- Sector Growth: 2,700 companies, 75,600 employees, +21% revenue growth, and €1.4 billion in R&D investments (+10%).
- Challenges: Despite high startup rates, business failures are increasing. Financing remains critical, with strong support from Bpifrance.
- Employment: Slight decline in 2024, but 83% of companies plan to hire in 2025 (+2,000 jobs).
- Tech Focus: Digital health and AI are booming, with 450 companies using AI and 76% in the commercialization phase.
- Government Support: €682 million allocated by Bpifrance, focusing on mental health and prevention. Tax incentives like CIR and JEI benefit 86% of companies.
- Sector Insights: Biotech focuses on oncology, neurology, and infectious diseases. Medtech faces MDR challenges. Digital health is advancing diagnostics and patient monitoring.
- Outlook: The sector is set for growth, driven by innovation, partnerships, and public support, though financing and regulatory compliance remain key hurdles.
2024 ended on a high note with the celebration of IDD’s 20th anniversary alongside our valued partners and clients. This milestone was made possible thanks to the dedication and expertise of our team members, the true driving force behind our achievements.
In 2025, we look forward to continuing our collaboration on your development plans, regulatory challenges, and business operations. May this year bring fruitful partnerships, growth, and exciting new opportunities.
Stéphane Simon joins as VP, Chief Pharmaceutical Officer of IDD and CEO of Bio Valys Pharma. With 30 years of experience as a Qualified Person and a strong background in regulatory leadership, he will lead the development of a new strategic pillar focused on pharmaceutical commercialization.
Anne Walter takes on the role of Director of Pharmaceutical Affairs & Exploitation. With over three decades of experience in quality, pharmacovigilance, and compliance, she will strengthen IDD’s regulatory foundations and help shape its future strategic offerings.
Their appointments represent a significant milestone in IDD’s growth, reinforcing our expertise and expanding our capabilities for the years ahead.
The feedback session was a real success, thanks in particular to the presentation by our colleague Lorraine Balin. Her clear and insightful overview of the major regulatory developments provided valuable guidance on best practices and future directions for the pharmaceutical industry.
To extend the impact of this session, we are pleased to share a visual summary highlighting the key regulatory milestones discussed during the event. This infographic serves as a concise and educational tool to revisit the essential takeaways from a day rich in knowledge and exchange.
